Hamid Nasri1, Saeed Behradmanesh2, Ali Ahmadi3, Mahmoud Rafieian-Kopaei4. 1. Department of Nephrology, Division of Nephropathology, Isfahan University of Medical Sciences, Isfahan, Iran. 2. Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran. 3. Department of Epidemiology, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 4. Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Abstract
BACKGROUND:Vitamin D is an important mediator of calcium metabolism. It has also been implicated as a potential contributor to the pathophysiology of various extra-skeletal conditions, consisting hypertension, renal disease, and insulin resistance. OBJECTIVES: The primary objective of this study was to determine whether oral vitamin D (cholecalciferol) supplementation can lead to improvement of blood pressure in type 2 diabetes patients. PATIENTS AND METHODS: This study was a double blind clinical trial conducted on 60 type 2 diabetes mellitus patients. Exclusion criteria were taking calcium, vitamin D supplements or any drugs effecting calcium and vitamin D metabolism in the past 6 months. Patients were administered weekly vitamin D supplementation (50000 units) for 12 weeks. Serum 25-Hydroxy vitamin D [25(OH)D] level was measured with ELISA method. RESULTS: Five patients (8.3%) had vitamin D deficiency, 27 (45%) had insufficient levels of vitamin D and in 28 (45%) patients vitamin D level was within normal limits. The means of systolic blood pressure (BP) and diastolic BP in patients before intervention were 121 and 80.5 mmHg; after intervention they were 110 and 76.3 mmHg, respectively. After intervention, systolic and diastolic blood pressure levels were significantly less than control group (p< 0.01). CONCLUSIONS: In this study we found that weekly vitamin D supplementation (cholecalciferol; 50,000 units for 12 weeks) had beneficial effect on the level of blood pressure in type 2 diabetic patients. Thus, oral vitamin D may help in improvement of hypertension in these patients.
RCT Entities:
BACKGROUND:Vitamin D is an important mediator of calcium metabolism. It has also been implicated as a potential contributor to the pathophysiology of various extra-skeletal conditions, consisting hypertension, renal disease, and insulin resistance. OBJECTIVES: The primary objective of this study was to determine whether oral vitamin D (cholecalciferol) supplementation can lead to improvement of blood pressure in type 2 diabetespatients. PATIENTS AND METHODS: This study was a double blind clinical trial conducted on 60 type 2 diabetes mellituspatients. Exclusion criteria were taking calcium, vitamin D supplements or any drugs effecting calcium and vitamin D metabolism in the past 6 months. Patients were administered weekly vitamin D supplementation (50000 units) for 12 weeks. Serum 25-Hydroxy vitamin D [25(OH)D] level was measured with ELISA method. RESULTS: Five patients (8.3%) had vitamin D deficiency, 27 (45%) had insufficient levels of vitamin D and in 28 (45%) patientsvitamin D level was within normal limits. The means of systolic blood pressure (BP) and diastolic BP in patients before intervention were 121 and 80.5 mmHg; after intervention they were 110 and 76.3 mmHg, respectively. After intervention, systolic and diastolic blood pressure levels were significantly less than control group (p< 0.01). CONCLUSIONS: In this study we found that weekly vitamin D supplementation (cholecalciferol; 50,000 units for 12 weeks) had beneficial effect on the level of blood pressure in type 2 diabeticpatients. Thus, oral vitamin D may help in improvement of hypertension in these patients.
Entities:
Keywords:
Hypertension; Type 2 diabetes patients; Vitamin D
Authors: K S Polonsky; B D Given; L Hirsch; E T Shapiro; H Tillil; C Beebe; J A Galloway; B H Frank; T Karrison; E Van Cauter Journal: J Clin Invest Date: 1988-02 Impact factor: 14.808
Authors: Suzanne E Judd; Charity J Morgan; Bhupesh Panwar; Virginia J Howard; Virginia G Wadley; Nancy S Jenny; Brett M Kissela; Orlando M Gutiérrez Journal: Int J Stroke Date: 2016-01 Impact factor: 5.266